JNJ Johnson & Johnson
USHealthcareAs of 2026-10-08
Why JNJ matters now
Johnson & Johnson (JNJ) is a US stock in Healthcare. The latest InvestLog snapshot shows $256.46 with -0.77% on the session and $618.04B in market capitalization; recent performance reads 1-month -0.70% and YTD +10.36%.
The latest financial table shown here is Q1 2026, with revenue of $24.06B, net income of $5.24B, and EPS of $2.14. Investors can compare that operating picture with valuation signals such as P/E 21.44 and FCF yield 3.2%.
InvestLog's latest related AI research is a Rating Change note titled "RBC Capital raises JNJ target to $290". The latest indexable market news headline is "HALO Wins Court Order Blocking Merck's Keytruda SC in Europe" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $255.00; recent insider activity includes Wengel Kathryn E filing M-Exempt; recent congressional disclosure data includes Ro Khanna Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
21.44
PEG
0.24
P/B
6.88
P/S
5.71
EV/EBITDA
17.41
DCF Value
$326.99
FCF Yield
3.2%
Div Yield
2.3%
Margins & Returns
Gross Margin
69.1%
Operating Margin
26.9%
Net Margin
21.8%
ROE
26.3%
ROA
10.5%
ROIC
13.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $24.06B | $5.24B | $2.14 |
| Q1 2026 | $24.06B | $5.24B | $2.14 |
| Q4 2025 | $24.56B | $5.12B | $2.10 |
| FY 2025 | $94.19B | $26.80B | $11.03 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$251.55
Target (Median)
$255.00
Target Range
$208.00 - $283.00
Trading Activity
Insider Trades
Congress Trades
Related AI Research
RBC Capital raises JNJ target to $290RBC Capital 上调目标价 强生 (JNJ) 至 $290
On 2026-10-06, RBC Capital raised its JNJ price target to $290.RBC Capital 于 2026-10-06 将 JNJ 目标价上调至 $290。
BofA Securities raises JNJ target to $278BofA Securities 上调目标价 强生 (JNJ) 至 $278
On 2026-09-29, BofA Securities raised its JNJ price target to $278.BofA Securities 于 2026-09-29 将 JNJ 目标价上调至 $278。
HSBC raises JNJ target to $320 from $290HSBC 上调目标价 强生 (JNJ)：$290 → $320
On 2026-09-10, HSBC raised its JNJ price target to $320 from $290 (+10.3%).HSBC 于 2026-09-10 将 JNJ 目标价上调至 $320，此前为 $290，变动幅度 +10.3%。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US
Exchange
—
Beta
0.26
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.